- Male adults (aged 18 to 65 years) with Haemophilia A (all severity levels) who
currently use FVIII treatment either prophylactically or on-demand using traditional
factor VIII delivery mechanisms.
- Patients advised for any reason by their physician to switch to a new factor VIII
delivery device, namely FuseNGO, before receiving any details about this study or
Patients who requested to be treated with a new factor VIII delivery device namely
FuseNGO, before receiving any details about this study.
- Patients not previously recommended by their physician to switch to this new factor
VIII delivery system or Patients who did not previously ask their physician to be
switched to this new factor VIII delivery system.
- Patients for which it is anticipated that 10 infusions will not occur in the 12
months following their inclusion in the study.